A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of at least 6 months, as determined by the investigator * Histologically or cytologically confirmed with unresectable or metastatic HER2-positive advanced solid tumors * Must be relapsed or refractory after prior treatment for metastatic disease that included a taxane and trastuzumab or must have received first-line induction therapy for advanced disease a pertuzumab plus trastuzumab-based regimen or a T-DXd-based regimen * Participants with new, untreated, progressive, or stable brain metastases are eligible Exclusion Criteria: * Participation in any other clinical study involving an investigational drug or device within 4 weeks prior to the first dose of study treatment * Any intracranial lesion (brain metastasis) that requires immediate local therapy, such as surgery or radiation, or systemic corticosteroids at the time of enrollment